Monthly SUBLOCADE® May Be A Treatment Option For Opioid Use Disorder During & After Pregnancy 

The use of monthly SUBLOCADE® (a branded medication that combines buprenorphine and naloxone in an extended-release formulation) to treat women with opioid use disorder (OUD) during pregnancy demonstrated no increased risk and is consistent with the established buprenorphine safety profile., according to a study. ;The researchers stated that the findings support “consideration of implementing buprenorphine extended-release medication as part of evidence-based practice that prioritizes OUD treatment access, patient stability, and patient choice during the perinatal period.” ;

The researchers analyzed electronic medical record (EMR) data and conducted a literature review of relevant reports of pregnancy and . . .